gosset trials
Search clinical trials by free text plus drug, disease, target, sponsor, phase, status, registry and date filters.
gosset trials [SEARCH] [filters] [output flags]SEARCH (optional) is free text matched against the trial's NCT id, acronym or title.
Filters
| Flag | Accepts | Example |
|---|---|---|
SEARCH | free text or an NCT id | gosset trials NCT06651281 · gosset trials semaglutide |
--drug | drug name or id | --drug tirzepatide |
--disease | disease name or id; includes narrower diseases | --disease "ulcerative colitis" |
--target | target name or id | --target TL1A |
--sponsor | sponsor company name or id | --sponsor Pfizer |
--phase | comma-separated | --phase 3 · --phase 2,3 |
--status | trial status(es) | --status Active · --status Completed,Terminated |
--registry | ctg (default), eu_ctis, another registry code, or all | --registry all |
--since / --until | completion date YYYY-MM-DD | --since 2025-01-01 |
--industry-only | flag | trials with an industry sponsor or collaborator |
--has-results | flag | trials with reported results |
Default sort: latest completion date first.
status is Gosset's summary: Active, Completed, Terminated or Unknown. A registry status such as Recruiting also works and is mapped to it. The registry's own wording is in the official_status field.
Registry scope
Trials default to ClinicalTrials.gov. Add --registry all to include EU CTIS, ChiCTR and the other registries Gosset collects.
More filters (primary completion dates, endpoint categories, ECOG and prior lines, whether the program progressed) are available through --where.
Examples
# Phase 3 semaglutide trials
gosset trials semaglutide --phase 3 --limit 5 --tablenct_id phase status drug diseases primary_completion_date
----------- ----- ------ ----------- ------------------------- -----------------------
NCT06934655 3 Active semaglutide pediatric obesity 2030-11-01
NCT07021937 3 Active semaglutide obesity 2031-04-30
NCT07090343 3 Active semaglutide obesity, Overweight 2030-09-01
NCT07845994 3 Active semaglutide hypothalamic obesity (HO) 2031-02
NCT07797036 3 Active semaglutide metabolic syndrome 2030-09-01
… showing 5 of 137 total# One trial by NCT id
gosset trials NCT06651281 --fields nct_id,title,phase,status,primary_completion_date[
{
"nct_id": "NCT06651281",
"title": "Tulisokibart Extension Study in Crohn's Disease or Ulcerative Colitis",
"phase": "3",
"status": "Active",
"primary_completion_date": "2037-12-17"
}
]# TL1A trials in ulcerative colitis, every registry
gosset trials --target TL1A --disease "ulcerative colitis" --registry all --limit 5 \
--fields nct_id,registry,phase,status,drug --tablenct_id registry phase status drug
----------- -------- ----- ------ ------------
NCT06651281 ctg 3 Active tulisokibart
eu_ctis 3 Active tulisokibart
eu_ctis 3 Active duvakitug
NCT07185009 ctg 3 Active duvakitug
chictr 3 Active afimkibart
… showing 5 of 92 totalTrials from other registries have no NCT id. Their own id is in trial_id.
# Industry Phase 3 obesity trials completing from 2025 on
gosset trials --disease obesity --phase 3 --industry-only --since 2025-01-01 --limit 5 \
--fields nct_id,phase,status,drug,completion_date --tablenct_id phase status drug completion_date
----------- ----- ------ ----------------------- ---------------
NCT07253285 3 Active cagrilintide 2033-09-20
NCT07817875 3 Active tirzepatide 2032-12
NCT06672939 3 Active orforglipron 2031-01
NCT06439277 3 Active tirzepatide 2030-12
NCT07037433 3 Active maridebart cafraglutide 2030-09-29
… showing 5 of 184 total# A drug's trials that have reported results
gosset trials --drug tulisokibart --has-results --fields nct_id,phase,status --tablenct_id phase status
----------- ----- ---------
NCT06052059 3 Active
NCT06956235 2 Active
NCT04996797 2 Completed
NCT05013905 2 Completed
NCT04676178 1 CompletedConditions on the drug or sponsor
--where reaches into the trial's main drug and its sponsor:
# Phase 3 atopic dermatitis trials of small molecules
gosset trials --disease "atopic dermatitis" --phase 3 --where "drug.modality=Small Molecules" \
--limit 5 --fields nct_id,drug,status --tablenct_id drug status
----------- ------------ ------
NCT06807281 abrocitinib Active
NCT03568318 upadacitinib Active
NCT06461897 upadacitinib Active
NCT07784816 girocitinib Active
NCT07823595 abrocitinib Active
… showing 5 of 124 total# TL1A Phase 2 and 3 trials sponsored by big pharma or biotech
gosset trials --target TL1A --phase 2,3 --where 'sponsor.type=Big Pharma | sponsor.type=Biotech' \
--limit 5 --fields nct_id,phase,drug --tableLine of treatment and population
Each trial has line_of_treatment: one or more of first-line, second-line, third-line-plus, subsequent, maintenance, adjuvant and neoadjuvant. Ask for it with --fields:
gosset trials --disease "multiple myeloma" --phase 3 --fields nct_id,title,line_of_treatment --limit 3 --tablenct_id title line_of_treatment
----------- ------------------------------------------------------------ -----------------
NCT07887984 Bispecific Antibody Therapy vs ASCT as Consolidation for New first-line
NCT07903506 iMMagine-6: Anitocabtagene Autoleucel vs Auto-SCT in Newly D first-line
NCT07887672 iMMagine-4: Anitocabtagene Autoleucel vs Standard of Care in first-line
… showing 3 of 350 totalThe query behind gosset trials does not filter on line_of_treatment yet. Filter in jq instead: jq '[.[] | select(.line_of_treatment | index("maintenance"))]'.
Trials also carry the population their eligibility criteria describe (beta). Each field comes with the sentence it rests on, and is absent when the text does not say:
Field and --where filter | Values |
|---|---|
treatment_naive | true or false |
stage_group Added 12 November 2026. Filter trials by disease stage at entry with --where stage_group. | early, locally_advanced, advanced, metastatic |
severity Added 12 November 2026. Filter trials by required severity with --where severity. | mild, moderate, severe |
treatment_setting Added 12 November 2026. Filter trials by treatment setting with --where treatment_setting. | neoadjuvant, adjuvant, perioperative, first_line, second_line, third_line_or_later, previously_treated, maintenance, induction, consolidation |
prior_therapy_classes Added 16 November 2026. Filter trials by the therapy patients must have had before entry, with --where prior_therapy_classes. | Free text, for example pd-1 or platinum; matches part of a class name, ignoring case |
# Phase 3 trials that require prior anti-PD-1 therapy
gosset trials --phase 3 --where prior_therapy_classes=pd-1 --fields nct_id,title,prior_therapy_classes --limit 3[
{
"nct_id": "NCT06498635",
"title": "INSIGHT: Durvalumab vs Surveillance in Early-Stage NSCLC",
"prior_therapy_classes": {
"evidence": "complete (R0) resection of NSCLC ... at least two cycles of neoadjuvant platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 therapy",
"values": ["surgical resection", "platinum-based chemotherapy", "anti-PD-1/PD-L1 therapy"]
}
},
...
]values are the classes as the criteria name them. evidence is the eligibility text.
# Phase 3 trials in metastatic disease, with the sentence the stage comes from
gosset trials --where stage_group=metastatic --phase 3 --fields nct_id,stage_group --limit 2[
{
"nct_id": "NCT07365319",
"stage_group": {
"evidence": "Participant has histologically or cytologically confirmed Stage 4 NSCLC",
"stated": ["Stage 4"],
"system": null,
"values": ["metastatic"]
}
},
{
"nct_id": "NCT06697301",
"stage_group": {
"evidence": "Have histologically or cytologically confirmed Stage 3 (unresectable) or Stage 4 metastatic melanoma per AJCC 8th ed.",
"stated": ["Stage 3", "Stage 4"],
"system": "AJCC",
"values": ["locally_advanced", "metastatic"]
}
}
]Piping to jq
# NCT id and title for Phase 3 GLP-1 receptor trials
gosset trials --target GLP-1R --phase 3 --limit 3 \
| jq -r '.[] | "\(.nct_id)\t\(.title)"'NCT06934655 Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
NCT07817875 Tirzepatide in Pediatric Participants 6 to Less Than 12 Years of Age With Obesity
NCT07795164 Pemvidutide in Noncirrhotic MASH# NCT ids to feed into ptrs (see Predictions)
gosset trials --drug tirzepatide --phase 3 | jq -r '.[].nct_id'Receptor or ligand?
Some target names name both a hormone and its receptor. --target GLP-1R finds the receptor agonists (semaglutide, tirzepatide). --target GLP-1 matches the hormone itself and returns far fewer trials.
Useful fields
Run gosset schema trials for all of them. Common ones: nct_id, trial_id, registry, title, study_code, phase, status, official_status, drug, other_drugs, diseases, sponsors, lead_sponsor, enrollment, start_date, primary_completion_date, completion_date, primary_endpoints, has_results, endpoints_met_all, endpoints_met_any, line_of_treatment, treatment_naive, stage_group, severity, treatment_setting, prior_therapy_classes.